Source - SMW
SciFluor Life Sciences, a subsidiary of Allied Minds, has  announced positive top-line results of a phase 1/2 trial studying the treatment of 'wet' age-related macular degeneration  patients with SF0166, the company's lead eye drop drug for back of the eye diseases. 

The double masked phase 1/2 study assessed the safety, tolerability and preliminary efficacy of SF0166 in 42 evaluable subjects with neovascular (wet) AMD who were randomised 1:1 to self-administer an eye drop containing either a 2.5% or a 5% solution of SF0166 twice-a-day for 28 days.

It said the primary outcome measure of safety was clearly achieved with no drug-related serious adverse events observed in the study throughout the 28-day course of treatment as well as during the 28-day follow-up period. 

Ocular adverse events were recorded in the treated eyes of 5 patients; all events were mild or moderate in severity, with one considered possibly drug-related.

At 9:30am: (LON:ALM) Allied Minds PLC share price was -1.25p at 136.75p